Thermo Fisher Secures Contracts with Pharma Production Moving to US, CEO Reports

• Thermo Fisher acquired Sanofi's Ridgefield, New Jersey facility last year specifically to expand capacity for helping customers reshore production to the U.S.
• The CEO noted that biotech funding is improving and pharmaceutical companies 'feel very confident' working with the U.S. administration, leading to increased pipeline investments
• Analysts viewed the messaging as constructive, with the company expressing optimism while maintaining realistic expectations for 2026 performance

Summary

Key Development:

Thermo Fisher Scientific has secured multiple contracts to assist pharmaceutical clients relocating production from Europe and Asia to the United States, CEO Marc Casper announced at the J.P. Morgan Healthcare Conference on January 13, 2026.

Main Details:

• The reshoring trend is expected to provide significant tailwinds for Thermo Fisher in 2027 and 2028
• The movement aligns with President Trump's push for domestic pharmaceutical manufacturing onshore
• Delayed tariffs on imported medicines have already accelerated reshoring projects
• Thermo Fisher acquired Sanofi's Ridgefield, New Jersey facility in 2025 specifically for capital expansion to support customer reshoring efforts

Market Implications:

• Casper noted improving biotech funding conditions and increased pharmaceutical industry confidence in working with the U.S. administration
• Companies are showing greater willingness to invest in their pipelines
• Thermo Fisher sees "an improving set of end markets" overall
• Evercore ISI analyst Vijay Kumar characterized the company's messaging as "constructive," noting management expressed optimism without raising 2026 expectations

Sector Impact:

The pharmaceutical services business stands to benefit from the broader industry shift toward U.S.-based manufacturing, driven by both policy pressure and strategic considerations around supply chain security.

Company Focus:

Thermo Fisher Scientific, a major medical equipment manufacturer, is positioning itself as a key enabler of the pharmaceutical reshoring trend through expanded production capacity and strategic acquisitions.